Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells.
about
Current developments in adenovirus-based cancer gene therapyAnalysis of genetic heterogeneity in the HCAR adenovirus-binding Ig1 domain in a Caucasian Flemish populationIn situ transduction of target cells on solid surfaces by immobilized viral vectorsParadigms lost-an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesisRecruitment of nectin-3 to cell-cell junctions through trans-heterophilic interaction with CD155, a vitronectin and poliovirus receptor that localizes to alpha(v)beta3 integrin-containing membrane microdomainsOptimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.Artificial extension of the adenovirus fiber shaft inhibits infectivity in coxsackievirus and adenovirus receptor-positive cell lines.Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review)Head and neck cancer: gene therapy approaches. Part 1: adenoviral vectors.Tissue-specific promoters for cancer gene therapy.Oncolytic viral therapies.Coxsackievirus and adenovirus receptor expression in human endometrial adenocarcinoma: possible clinical implicationsThe Coxsackievirus and Adenovirus Receptor: Glycosylation and the Extracellular D2 Domain Are Not Required for Coxsackievirus B3 Infection.Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.Protein transduction domains fused to virus receptors improve cellular virus uptake and enhance oncolysis by tumor-specific replicating vectors.Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection.Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line.The roles of cell surface attachment molecules and coagulation Factor X in adenovirus 5-mediated gene transfer in pancreatic cancer cells.Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro.Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment.Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').PCI-enhanced adenoviral transduction employs the known uptake mechanism of adenoviral particles.Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids.The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells.Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase.Highly efficient and specific modulation of cardiac calcium homeostasis by adenovector-derived short hairpin RNA targeting phospholamban.A novel tetracycline-controlled transactivator-transrepressor system enables external control of oncolytic adenovirus replication.Tamoxifen-regulated adenoviral E1A chimeras for the control of tumor selective oncolytic adenovirus replication in vitro and in vivo.
P2860
Q24683229-9D38CEC4-B0D1-4417-B6DA-DADD03E6D563Q24798455-4CC4178F-AE15-4B2E-9D14-433AE38436F3Q24800547-9A6DED42-A680-4133-84C1-E40ECD9DAB76Q26787279-B5B8BDA8-9D0F-4449-8B21-67F8CF682F14Q28205394-95A8D850-CAD7-4387-89AE-655E0000E2E6Q33647321-44B79926-F210-447B-93AD-DAEEE786822BQ34330435-DD154218-803B-4283-B813-9D7EF3E71A4CQ34433546-0DA03065-09BC-489D-AEA5-2273CF4B503AQ34534285-CCDF50C0-1C0C-49A0-84EE-7B15CC238E40Q35779378-1EC7E26A-8A1B-45BC-BB9D-6BCEE125B2FBQ35852258-641CFCD9-BFCA-4C11-BAE9-C1111801BDEAQ36737010-B72EE8ED-3AE4-47FF-B62B-EA4CD54A353EQ36950916-CE52E59D-E0CF-4440-A5A0-7BEE1ACEBE1FQ37227135-C12071CF-57AB-41A5-97FD-604FC3677842Q38333842-DDE67B97-8325-4FE2-B413-6182389F679EQ39235688-CD077995-A7E1-4EAD-BF64-02D8FB7A29A9Q39462630-94017551-C497-413E-8DD4-1F63A1DAE001Q39543933-B53428E7-F7A3-4B70-B529-BE5C75D43672Q39673855-AA4BA432-C3B3-479F-9993-964FF288BC61Q40429242-10816D02-C20B-441A-9DAE-BEC229D9BF5CQ40453395-C587362B-2230-44D9-ABA1-DC60149A9818Q40464384-9B39EA07-15AD-4196-853C-8D68C3DFD45FQ40651494-4CC6A769-7F52-40D5-8B77-26C17D27C2C3Q40659392-7FB347DB-404E-477F-99F8-93DD76753BE3Q43918965-28C6466D-3DAB-4410-B9F5-EB651F6F71B8Q45863016-79341E8F-EFC5-4C46-AB5F-653C3FC19568Q45864768-CF94A8DF-9846-4501-B59F-1BA5434AB29AQ45886514-3673F097-751D-4415-9A97-85698ED07B94
P2860
Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Trans-complementation of vecto ...... oorly permissive cancer cells.
@en
Trans-complementation of vecto ...... oorly permissive cancer cells.
@nl
type
label
Trans-complementation of vecto ...... oorly permissive cancer cells.
@en
Trans-complementation of vecto ...... oorly permissive cancer cells.
@nl
prefLabel
Trans-complementation of vecto ...... oorly permissive cancer cells.
@en
Trans-complementation of vecto ...... oorly permissive cancer cells.
@nl
P2093
P2860
P356
P1433
P1476
Trans-complementation of vecto ...... oorly permissive cancer cells.
@en
P2093
Bergelson JM
Pauschinger M
Scherübl H
Schultheiss HP
P2860
P2888
P304
P356
10.1038/SJ.GT.3301321
P577
2000-11-01T00:00:00Z
P5875
P6179
1051780743